Back to Search Start Over

EMERGEncy versus delayed coronary angiogram in survivors of out-of-hospital cardiac arrest with no obvious non-cardiac cause of arrest: Design of the EMERGE trial

Authors :
Olivier Varenne
Pierre Leroux
Alain Cariou
Thomas Loeb
Sophie Glippa
Cédric Daubin
Eric Roupie
Jean-Baptiste Lascarrou
Jean-Luc Diehl
Christian Spaulding
Aurélie Vilfaillot
Juliette Djadi-Prat
Caroline Hauw-Berlemont
Patrice Guerin
Christophe Andreotti
Emerge investigators
Gilles Chatellier
Lionel Lamhaut
Farzin Beygui
Source :
American Heart Journal. 222:131-138
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

Background In adults, the most common cause of out-of-hospital cardiac arrests (OHCA) is acute coronary artery occlusion. If an immediate coronary angiogram (CAG) is recommended for survivors presenting a ST segment elevation on the electrocardiogram (ECG) performed after resuscitation, there is still a debate regarding the best strategy in patients without ST segment elevation. Hypothesis Performing an immediate CAG after an OHCA without ST segment elevation on the post-resuscitation ECG and no obvious non-cardiac cause of arrest could lead to a better 180-day survival rate with no or minimal neurological sequel as compared with a delayed CAG performed 48 to 96 hours after the arrest. Design The EMERGE trial is a prospective national, randomized, open and parallel group trial, in which 970 survivors of OHCA will be randomized (1:1) to either immediate (as soon as possible after return of spontaneous circulation) or delayed (48 to 96 h) CAG. Participants will be OHCA patients with no ST segment elevation on the post resuscitation ECG and no obvious non-cardiac cause of arrest. The primary endpoint of the study is the 180-day survival rate with no or minimal neurological sequel corresponding to Cerebral Performance Category (CPC) 1 or 2. The secondary endpoints are: occurrence of shock during the first 48 hours, ventricular tachycardia and/or fibrillation during the first 48 hours, change in left ventricular ejection fraction between baseline and 180 days assessed by echocardiogram, neurological status evaluated by the CPC score at intensive care unit (ICU) discharge and day 90 neurological status assessed by the Glasgow Outcome Scale Extended score (GOSE) at 90 and 180 days, overall survival rate, and hospital length of stay. Summary The EMERGE trial is a prospective, multicenter, randomized, controlled trial that will assess the 180-day survival rate with no or minimal neurologic sequel in patients resuscitated from an OHCA without ST segment elevation and who will be managed with either immediate or delayed CAG.

Details

ISSN :
00028703
Volume :
222
Database :
OpenAIRE
Journal :
American Heart Journal
Accession number :
edsair.doi.dedup.....6a583452f67d8b1ce96ae6cd74ecfe65